Published in Drug Week, July 30th, 2004
Atacand is currently approved for the treatment of hypertension.
The sNDA submission is based primarily on results from the clinical trial program known as CHARM (Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity), the most comprehensive trial program completed to date with an ARB for heart failure. CHARM was an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.